Concomitant use of immunomodulators with anti-TNF in Crohn's disease: Yes or no?

Current Drug Targets

Volumn 11, Issue 2, 2010, Pages 176-178

  Meier, Johannes ^a   Sturm, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biologics; Concomitant therapy; Crohn's disease; Immunogenicity; Inflammatory bowel diseases

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG SAFETY; HUMAN; IMMUNOGENICITY; LYMPHOMA; MAINTENANCE THERAPY; MONOTHERAPY; OPPORTUNISTIC INFECTION; REMISSION; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950855862     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790309948     Document Type: Review

References (23)

1. Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-713 (Pubitemid 34977076)
2. Baert F, Noman M, Vermeire S, Van AG, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608 (Pubitemid 36204954)
3. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-1457 (Pubitemid 36831435)
4. Vermeire S, Louis E, Carbonez A, Van AG, Noman M, Belaiche J, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-2363
5. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-924 (Pubitemid 36389794)
6. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226
7. D'Haens G, Baert F, Van AG, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667
8. Sandborn W, Rutgeerts P, Reinisch W. One year data from the Sonic Study: A randomized, double blind, controlled trail comparing Infliximab and Infliximab plus Azathioprine to Azathioprine in Patients with Crohn's disease Naive to immunomodulators and biologic therapy. Gastroenterology 2009; 136(Suppl 1): A116.
9. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868 (Pubitemid 351790744)
10. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005; 34: 19-22. (Pubitemid 40502156)
11. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-553 (Pubitemid 38834038)
12. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563
13. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 (Pubitemid 34621118)
14. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-1254 (Pubitemid 44512213)
15. Vermeire S, Noman M, Van AG, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-1231 (Pubitemid 47300423)
16. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de GE, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-715
17. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Through serum infliximab: a predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis. Gut 2009; 2. [Epub ahead of print].
18. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van WM, de Groot ER, Wolbink G, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66: 253-256 (Pubitemid 46226064)
19. Bartelds GM, Wolbink GJ, Stapel S, Aarden L, Lems WF, Dijkmans BA, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006; 65: 1249-1250 (Pubitemid 44277411)
20. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-3789 (Pubitemid 44955878)
21. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226
22. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936 (Pubitemid 351451967)
23. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-508